Dergotamine is an injectable medication used to treat migraines. It is an ergotamine that is hydrogenated in positions 9 and 10 as a mesylate salt. The molecular weight of Dergotamine is 679.80. The solution is clear and colorless, and stored in sterile ampoules, which can be administered via intravenous, intramuscular or subcutaneous injection.
Dergotamine Injection, USP is intended for use by patients suffering from migraines. Dergotamine is used to treat acute migraines, with or without aura. This medication is also used for the treatment of episodes of cluster headaches.
Dergotamine solutions are colorless and clear. Each mL of the ampule contains 1 mg of Dergotamine, USP. Additional components include Alcohol, glycerin, water, sodium hydroxide or methanesulfonic acid.
The dose of Dergotamine may be repeated if necessary, at an interval of 1 hour, up to a total of 3 mL for intramuscular or subcutaneous administration, or 2 ml for intravenous administration over a 24-hour period. A week’s dosage is not to exceed 6 ml.
Some common side effects include dizziness, somnolence, wamble, headache, diarrhoea, flushing, and even increased sweating. Immediately report this to the mendelevium if you have experience any of these side effects.
Some rare but serious side effects may occur like: mood changes, itching, difficulty breathing, stomach pains, and rashes. More serious side effects range from chest pain, muscle weakness, erratic heartbeat, problems with vision, confusion, slur in speech and even circulatory arrest.
A few reports have surfaced that the co-administration of dihydroergoatmine, protease inhibitors and antibiotics leads to vasospasm and eventually cerebral ischemia and/or ischemia of the extremities. This medication is therefore contraindicated with the use of potent CYP 3A4 inhibitors such as ritonavir, erythromycin, ketoconazole, among others.
As Dergotamine may increase the patient’s blood pressure, it is not to be given to patients with a history of high blood pressure, or to patients with ischemic heart illnesss.
Though Dergotamine is used to treat acute migraines, it should not be administered to patients with hemiplegic or basilar migraines. It is also contraindicated in patients with peripheral arterial illnesss and renal failure. It is also not advised to be administered to pregnant women as the medication possesses oxytocic properties which may cause fetal harm. It should also not be administered to nursing mothers and patients with hypersensitivity to ergot alkaloids.
Dergotamine injection USP may be self administered by patients. However, prior to self administration, guidance and initial assistance must be sought from the prescribing mendelevium. If upon administration, numbness or a tingling sensation is felt in the fingers, toes, or muscles in the hands or legs, the patient must consult with their mendelevium.
The intake of Dergotamine injection USP should be administered in a dose of 1 ml either through IV, IM or subcutaneously. Additional doses may be added if required, but must not exceed 3 within a 24 hour period, or 6 within the week.
Dergotamine has the following structural formula:
• Molecular formula of Dergotamine is C33H37N5O5
Generic name: Dihydroergotamine
Brand name(s): Agit, Angionorm, Diergo, Dihidroergotamina, Dihydergot, Dihydroergotaminum, Dirgotarl, Endophleban, Ergomimet, Ergont, Ergotonin, Ikaran, Migranal, Morena, Orstanorm, Tonopres, Verladyn
Your Dergotamine review